S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Kimberly-Clark Products Post Weak Quarter Despite Raising Prices

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)
Kimberly-Clark Products Post Weak Quarter

Key Points

  • Organic sales rose by $5 and sales increased by 1% year over year. 
  • North American organic sales fell by 2% and increased  11%.
  • Operating profits fell slightly to $655 million, down from $657 million in the same quarter last year.
  • 5 stocks we like better than Kimberly-Clark

Kimberly-Clark Corporation NYSE: KMB witnessed rising costs, slowing sales due to weakness in consumer demand in North America and dollar strength weighing on its global top line during the latest quarter. Increasing inflation and a decline in purchasing power clearly affects how consumers pick and choose products.

As inflation continues to remain hot, customers have chosen substitute products, a crucial factor in why sales volumes have declined in North America even as consumer sentiment continues to rise. Most consumer companies, including Kimberly-Clark products, have increased prices by around 9%, consistent with the CPI figures.

Segment Overview

Here's a quick look at Kimberly-Clark segment performance:
  • Personal care: Third-quarter sales for personal care came in at $2.6 billion, a decline of 1% year-over-year. Foreign exchange resulted in a 4% decline in sales despite prices that increased by 8% and a product mix that improved by 1% during the quarter. Personal care products tend to be less price sensitive but substitution is a factor that affects volumes. North American volumes fell by 5% during the quarter.
  • K-C professional segment: This segment witnessed the fastest growth. Sales increased by 5% and net selling price increased by 14% but volume fell by 5%. The segment is exposed primarily to nonretail consumers, which allows Kimberly-Clark professionals to make up for a lack of volume through increases in prices. Volume is likely to remain muted due to a number of factors, including fewer offices requiring products compared to previous years, as trends such as working from home affect the demand for commercial real estate.
  • Consumer tissue segment: Total sales increased by 2% during the quarter, despite the fact that the net selling price increasing by 9%. Consumer tissue continues to remain relatively steady in terms of volume and shouldn’t face too much volatility going forward. 
Increasing costs have started to affect operations, with inflation affecting input, marketing, labor, transportation and research costs. The cost of products sold fell slightly but operating costs increased by 7% during the quarter, which resulted in operation profit declining by $2 million YOY. For the last nine months, the costs of products sold increased by 7% as well. Operating margins came in at 13%, the same as the previous year. Some of the cost increases have been mitigated by reducing the cost of goods sold. The increase in costs led to net income decline of 2% and fell to $470 million. EPS fell by 1%, coming in at $1.38 per share. Cash and cash equivalents increased slightly during the quarter, with a change in cash and cash equivalents coming in at $50 million and total money coming in at $362 million.

The company’s valuation is relatively modest despite headwinds and is similar to other S&P 500 companies such as Procter and Gamble NYSE: PG. The current price-to-earnings ratio (P/E) stands at 22 with a dividend of 4%. Investors should remain relatively neutral on the stock.

Kimberly-Clark continues to address slow and low growth by improving product offerings and expanding market geography. This will allow them to introduce newer categories and improve market penetration in Asia, South America and Africa. For example, the company has created a range of Huggies diapers, which will allow them to improve the product category in diapers by offering multiple price points. Category market share is as high as 50% and countries such as China remain central to management’s plan to improve future sales.


Risks largely stem from competition and substitution. Many consumers could switch to competitors' brands if inflation continues to run hot. While Kimberly-Clark’s product range is less price sensitive than other consumer goods, it is still vulnerable to global slowdowns. China reopening should reduce some of the volume issues, but overall, the stock will remain under pressure until economies become more steady, along with inflation.

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Should you invest $1,000 in Kimberly-Clark right now?

Before you consider Kimberly-Clark, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kimberly-Clark wasn't on the list.

While Kimberly-Clark currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Kimberly-Clark (KMB)
4.68 of 5 stars
$125.45+1.3%3.89%24.13Hold$132.43
PG&E (PCG)
2.8296 of 5 stars
$16.29-1.9%0.25%15.51Moderate Buy$18.78
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Search Headlines: